Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV

IF 1.7 4区 医学 Q3 INFECTIOUS DISEASES HIV Research & Clinical Practice Pub Date : 2024-06-03 DOI:10.1080/25787489.2024.2339576
Arianna E. Kousari, Melissa P. Wilson, Kellie L. Hawkins, Mohamed Mehdi Bandali, Andrés F. Henao-Martínez, Edward M. Gardner, Kristine M. Erlandson
{"title":"Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV","authors":"Arianna E. Kousari, Melissa P. Wilson, Kellie L. Hawkins, Mohamed Mehdi Bandali, Andrés F. Henao-Martínez, Edward M. Gardner, Kristine M. Erlandson","doi":"10.1080/25787489.2024.2339576","DOIUrl":null,"url":null,"abstract":"Weight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF). Doravirine (DOR) has been identified as a relatively “weight-neutral” drug; h...","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"45 1","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Research & Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/25787489.2024.2339576","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Weight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF). Doravirine (DOR) has been identified as a relatively “weight-neutral” drug; h...
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
艾滋病毒感染者从基于整合酶抑制剂或替诺福韦-阿拉非那胺的抗逆转录病毒疗法转为基于多拉韦林的抗逆转录病毒疗法后的体重变化
关于整合酶链转移抑制剂(INSTIs)和替诺福韦阿烯酰胺(TAF)体重增加的描述很多。多拉韦林(DOR)已被确定为一种相对 "体重中性 "的药物;它是一种 "中性 "药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.90
自引率
6.20%
发文量
15
期刊最新文献
A closer look: factors impacting HIV durable viral suppression among a cohort of clinic attendees in Trinidad & Tobago. Evaluation of the effect of 48 weeks of BIC/F/TAF and DRV/c/F/TAF on platelet function in the context of rapid ART start. 'It is scary to pause treatment': perspectives on HIV cure-related research and analytical treatment interruptions from women diagnosed during acute HIV in Durban, South Africa. Impacts of a multipronged initiative with community HIV clinics to support retention and re-engagement in HIV care. Heterogeneity of provider preferences for HIV Care Coordination Program features: latent class analysis of a discrete choice experiment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1